Multiplex8+: Prospective clinical validation of a highly accurate BCa diagnostic test
Project name: Multiplex8+: Prospective clinical validation of a highly accurate BCa diagnostic test to guide personalised-effective treatment, predict therapy response and prognosis.
Call: 09I01-03-V01 - Call for submission of applications for the provision of mechanism funds, aimed at supporting projects that have been awarded the seal of excellence (Seal of Excellence) in the wording of amendment no. 2
Investment: 1. Support for international cooperation and involvement in Horizon Europe projects and the EIT - European Institute of Innovation and Technology
Component: 9. More effective Management and strengthening of Research, Development and Innovation funding
Type of action: Recovery and Resilience Plan of the Slovak Republic 2021 - 2027 (RRP, Component 9)
Granting authority: Ministry of Economy of the Slovak Republic
Project starting date: 04/2024
Project end date: 09/2025
Project duration: 18 months
Estimated budget: 3 566 950,00 €
Abstract
Breast cancer (BCa) is the deadliest cancer primarily affecting women, with 2,3M new cases globally in 2020. This number is projected to surpass 3M by 2040 due to factors like aging, pollution, hormone use, lifestyle, and obesity. In the EU, about 360k cases affect 1 in 7 women, resulting in roughly 90k annual deaths.
Our mission is to drastically reduce the number of non-responders and relapse rates of BCa by ca. 50% and save thousands of lives each year.
Multiplex8+ test offers a paradigm-shifting personalized BCa cancer Dx test, which combines proprietary, patented, innovative RNA-based visualization and sequencing technologies in a single test. This reduces biases, eliminates diagnostic errors, and allows the profiling of more than 20,000 human genes, yielding deep insight into tumor biology. Information is then used to generate a report that precisely identifies patient-specific BCa profiles and provides the most effective personalized treatment options to inform oncologists’ decision-making process.
Multiplex8+ is the first and only single test for BCa patients that can simultaneously predict:
- the benefit of chemotherapy in adjuvant setup (after surgery) with near-perfect agreement at the single sample level;
- the effectiveness of various chemotherapies;
- the effectiveness of immunotherapy and other innovative therapies;
- the effectiveness of targeted treatment using antibody-drug conjugates (ADCs) by identifying multiple biomarkers that span several pathways involved in ADC efficacy.
This makes Multiplex8+ the only test available to select patients based on more than just a single ADC biomarker. All this together gives Multiplex8+ great potential to be the best BCa diagnostic test for finding the most effective and personalized treatment for every BCa patient. Even more, the initial application of Multiplex8+ is focused on BCa, but it can be adapted to other solid cancers.
Our case study conducted for Slovakia suggests that if used for all new BCa patients, Multiplex8+ would hold the promise of saving 250 lives and 52,8M EUR in healthcare and social security systems annually. When applied across the entire EU, this equates to 4,3B EUR and 20k lives saved each year.
RELATED NEWS:
https://www.multiplexdx.com/products/multiplex-eight-plus
Funded by the EU NextGenerationEU through the Recovery and Resilience Plan for Slovakia under the project No. 09I01-03-V01-00003.
About MultiplexDX
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.
Find out more about MultiplexDX on Corporate website, Facebook, LinkedIn, Twitter
